Investors

Upcoming/Past Events

Upcoming Events

Past Events

  • May 7 - May 11, 2017

    ARVO

    Poster presentation:
    A Phase 1/2 multidose, dose escalation study to evaluate RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular AMD (NVAMD) RXI-109: Self-delivering RNAi (sd-rxRNA) compound targeting connective tissue growth factor (CTGF) This poster presentation will show that RXI-109 has been found to be safe and well tolerated following intravitreal injection in subjects with advanced neovascular or wet age-related advanced macular degeneration (AMD) based on data collected thus far. The Study (RXI-109-1501) is still ongoing and the safety and clinical activity will be evaluated upon completion of the study. RXI-109 has the potential to fill an unmet medical need by reducing the retinal scarring that often results in AMD patients. RXI-109 is being developed as a potential therapeutic to preserve vision for a longer period of time as compared to standard of care treatments alone.

    Date and Time: Tuesday, May 9, from 11:00 AM to 12:45 PM EDT
    Presented by: Natalie Gagne
    Poster: #3210, Retina Session 342-AMD Clinical Research 2, Poster Area B

    Location

    Baltimore Convention Center, Maryland
  • Apr 30 - May 3, 2017

    19th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference

    Date and Time: Tuesday, May 2, 2017 9:30 am PDT
    Title: Reduced in vivo Tumor Growth Using CAR T-cells Treated ex vivo with PD-1 Targeting sd-rxRNA®
    Track: Oligonucleotide Discovery, Preclinical and Clinical

    Abstract: Silencing of immunosuppressive genes, such as PD-1, by ex vivo treatment with a self-delivering RNAi (sd-rxRNA) may improve the efficacy of CAR-T cells for the treatment of solid tumors. Meso-CAR-T cells (expressing antibody fragments that target mesothelin) were treated ex vivo with an anti-PD-1 sd-rxRNA. Direct tumor injection of these modified CAR-T cells in a mouse model of human ovarian cancer resulted in a statistically significant reduction of tumor growth.

  • Apr 26 - Apr 29, 2017

    Society for Investigative Dermatology 76th Annual Meeting

    Topical Application of Self-delivering RNAi (sd-rxRNA) Compounds for Reduction of Hyperpigmentation
    RXI-231: sd-rxRNA Targeting Tyrosinase (TYR)
    This poster will show that reduction of tyrosinase mRNA levels by sd-rxRNA in cultured cells leads to a decrease in visible pigmentation and melanin content, in line with the expected mechanism of action of an RNAi compound. In addition, as demonstrated ex vivo in pig skin, our proprietary formulation allows for the non-invasive penetration of sd-rxRNA compounds to the epidermal dermal junction where TYR-producing melanocytes reside. Consumer testing will initiate in May 2017.
    Date and Time: April 29, 2017 10:15 AM PDT
    Presented by: Melissa Maxwell
    Session 3: Pigmentation and Melanoma
    Poster #: 810, Exhibit Hall A

    Prevention of UVR Induced MMP1 Upregulation with an MMP1 Targeting Self-delivering RNAi (sd-rxRNA) Compound May Reduce the Effects of Skin Photo-aging
    RXI-185: sd-rxRNA Targeting Collagenase (MMP1)
    Results from a collaboration with DSM, one of the industry's leading suppliers of ingredients and innovative solutions for beauty care products, will be presented. This poster will show that RXI-185 is capable of reducing MMP1 mRNA levels and enzyme activity in cultured human dermal fibroblasts and in an in vitro human skin model after UVR-induced MMP1 upregulation. In addition, Fl-RXI-185 is capable of reducing MMP1 mRNA levels following topical administration in an ex vivo human skin model.
    Date and Time: April 29, 2017 10:15 AM PDT
    Presented by: Katherine Holton
    Session 3: Photobiology
    Poster #: 756, Exhibit Hall A

  • Mar 27 from 4:15 PM EDT to Mar 29, 2017

    2nd Annual Oligonucleotide and Peptide Therapeutics Conference

    March 28, 2017, Oligonucleotide Discovery and Delivery Track
    Pamela Pavco, PhD, Chief Development Officer, RXi Pharmaceuticals
    4:15pm: Presentation - Self-Delivering RNAi Compounds for the Treatment of Ocular Disorders

    March 29, 2017, Symposium 1: Oligonucleotides for Cancer Immunotherapy
    Alexey Eliseev, PhD, Chief Business Officer, RXi Pharmaceuticals
    1:25pm: Chair Session - Novel Immunomodulatory Nucleic Acids
    1:30pm: Presentation - Targeting Immune Checkpoints Using Self-Delivering RNAi Technology

  • Feb 15 - Feb 16, 2017

    2nd Annual Disruptive Growth and Healthcare Conference 2017

    Thursday, February 16, 2017 at 12:45 pm ET, Dr. Geert Cauwenbergh, RXi’s President and CEO, will present an overview of the Company's proprietary self-delivering RNAi (sd-rxRNA®) platform and the multiple development and commercialization opportunities available across a broad spectrum of therapeutic areas.

  • Feb 13 - Feb 14, 2017

    19th Annual BIO CEO & Investor Conference

    Tuesday, February 14, 2017 at 3:00 pm ET, Dr. Geert Cauwenbergh, RXi’s President and CEO, will present an overview of the Company's proprietary self-delivering RNAi (sd-rxRNA®) platform and the multiple development and commercialization opportunities available across a broad spectrum of therapeutic areas.

  • Jan 9 - Jan 11, 2017

    9th Annual Biotech Showcase™ 2017

    Monday, January 9, 2017 at 9:30am PT, Dr. Geert Cauwenbergh, RXi’s President and CEO, will present an overview of the Company’s novel self-delivering RNAi (sd-rxRNA®) technology and the multiple business development and commercial opportunities available based on this proprietary platform.

  • Oct 18 - Oct 19, 2016

    Bio Investor Forum

    Tuesday, October 18, 2016 at 9:30am PT, Dr. Geert Cauwenbergh, RXi’s President and CEO, will present an overview of the Company’s novel self-delivering RNAi (sd-rxRNA®) technology and the multiple business development and commercial opportunities available based on this proprietary platform.

  • Sep 27 - Sep 28, 2016

    16th Annual Biotech in Europe Forum Global Partnering and Investment Event

    Tuesday, September 27, 2016 at 10:45am CET, Dr. Geert Cauwenbergh, RXi’s President and CEO, will present an overview of the Company’s novel self-delivering RNAi (sd-rxRNA®) technology and the multiple business development and commercial opportunities available based on this proprietary platform.